Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Relief therapeutics  /  Relief therapeutics Holding

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 1,250 15 apr 2024 17:31
  • -0,010 (-0,79%) Dagrange 1,210 - 1,250
  • 3.456 Gem. (3M) 15,2K

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 439 440 441 442 443 ... 456 »» | Laatste | Omlaag ↓
  9. Forecast2006 29 november 2021 22:41
    Ad Hoc Announcement pursuant to Art. 53 LR,

    29 November 2021
    Relief Reports that its U.S. Collaboration Partner has Identified a Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir

    Geneva, Switzerland, November 29, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), has announced it completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with aviptadil in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. According to the press release, the analysis, conducted by Prof. David Schoenfeld, who they report is one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung, examined the subgroup of patients in the COVID-AIV trial (NCT 04311697) that remained in respiratory failure despite treatment with remdesivir. The press release also reported that the analysis identified a statistically significant (P=.03) 2.5-fold increased odds of being alive and free of respiratory failure at 60 days (the primary endpoint) and a statistically significant (P=.006) four-fold higher odds of being alive at day 60 among patients treated with aviptadil compared to those treated with placebo. The related NRx press release can be accessed through the following link.

    We gaan morgen verder omhoog.

    Kind regards,
    Forecast
  13. forum rang 10 DeZwarteRidder 30 november 2021 09:13
    quote:

    Beso schreef op 30 november 2021 08:00:

    [...]
    Dat geld in Genfit wat ik door jouw tip investeerde vermoedelijk nog veel minder LOL.
    Spaar me dus jouw "gouden" raad.
    Er bestaat ook iets als stop loss in geven wat je kan doen na +20% in 1 dag.
    Bij Genfit heb je nog steeds een hele goede kans om je geld terug te krijgen.
  15. Reader 30 november 2021 09:24
    REPORTS THAT PARENT COMPANY OF ITS COLLAB PARTNER, NRX PHARMACEUTICALS, ANNOUNCED IT COMPLETED AN ANALYSIS TO IDENTIFY CLINICAL EVIDENCE THAT INDICATES SUBSTANTIAL IMPROVEMENT AFTER TREATMENT WITH AVIPTADIL IN PATIENTS WITH CRITICAL COVID-19 AND RESPIRATORY FAILURE OVER EXISTING THERAPIES SUCH AS REMDESIVIR

    bron: degiro
  18. forum rang 10 DeZwarteRidder 30 november 2021 09:35
    quote:

    Forecast2006 schreef op 29 november 2021 22:41:

    Ad Hoc Announcement pursuant to Art. 53 LR,

    29 November 2021
    Relief Reports that its U.S. Collaboration Partner has Identified a Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir

    Geneva, Switzerland, November 29, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), has announced it completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with aviptadil in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. According to the press release, the analysis, conducted by Prof. David Schoenfeld, who they report is one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung, examined the subgroup of patients in the COVID-AIV trial (NCT 04311697) that remained in respiratory failure despite treatment with remdesivir. The press release also reported that the analysis identified a statistically significant (P=.03) 2.5-fold increased odds of being alive and free of respiratory failure at 60 days (the primary endpoint) and a statistically significant (P=.006) four-fold higher odds of being alive at day 60 among patients treated with aviptadil compared to those treated with placebo. The related NRx press release can be accessed through the following link.

    We gaan morgen verder omhoog.

    Kind regards,
    Forecast
    Opvallend is het ontbreken van aantallen patiënten en een duidelijke conclusie.
9.103 Posts
Pagina: «« 1 ... 439 440 441 442 443 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!